Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Differential COVID-19 infection rates in children, adults, and elderly: evidence from 38 pre-vaccination national seroprevalence studies

View ORCID ProfileCathrine Axfors, View ORCID ProfileAngelo Maria Pezzullo, View ORCID ProfileDespina G. Contopoulos-Ioannidis, Alexandre Apostolatos, View ORCID ProfileJohn P.A. Ioannidis
doi: https://doi.org/10.1101/2022.06.28.22277034
Cathrine Axfors
1Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California, USA
2Dept for Women’s and Children’s Health, Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cathrine Axfors
Angelo Maria Pezzullo
1Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California, USA
3Section of Hygiene, Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Angelo Maria Pezzullo
Despina G. Contopoulos-Ioannidis
1Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California, USA
4Division of Infectious Diseases, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Despina G. Contopoulos-Ioannidis
Alexandre Apostolatos
1Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California, USA
5Faculty of Medicine, Université de Montréal, Montreal, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John P.A. Ioannidis
1Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California, USA
6Departments of Medicine, of Epidemiology and Population Health, of Biomedical Data Science, and of Statistics, Stanford University, Stanford, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for John P.A. Ioannidis
  • For correspondence: jioannid@stanford.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background COVID-19 exhibits a steep age gradient of infection fatality rate. There has been debate about whether extra protection of elderly and other vulnerable individuals (precision shielding) is feasible, and, if so, to what extent.

Methods We used systematically retrieved data from national seroprevalence studies conducted in the pre-vaccination era. Studies were identified through SeroTracker and PubMed searches (last update May 17, 2022). Studies were eligible if they targeted representative general populations without high risk of bias. Seroprevalence estimates were noted for children, non-elderly adults, and elderly adults, using cut-offs of 20, and 60 years (or as close to these ages, if they were not available).

Results Thirty-eight national seroprevalence studies from 36 different countries were included in the analysis. 26/38 also included pediatric populations. 25/38 studies were from high-income countries. The median ratio of seroprevalence in the elderly versus non-elderly adults (or non-elderly in general, if pediatric and adult population data were not offered separately) was 0.90-0.95 in different analyses with large variability across studies. In 5 studies (all of them in high-income countries), there was significant protection of the elderly with ratio <0.40. The median was 0.83 in high-income countries and 1.02 in other countries. The median ratio of seroprevalence in children versus adults was 0.89 and only one study showed a significant ratio of <0.40.

Conclusion Precision shielding of elderly community-dwelling populations before the availability of vaccines was feasible in some high-income countries, but most countries failed to achieve any substantial focused protection of this age group.

summary 38 COVID-19 nationally representative seroprevalence studies conducted before vaccination campaigns were systematically identified. Median seroprevalence ratio in elderly versus non-elderly adults was 0.90-0.95, indicating no generally achieved precision shielding of elderly. In 5 studies, substantial protection (ratio <0.40) was observed.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Protocols

https://osf.io/xvupr

Funding Statement

The work of John Ioannidis is supported by an unrestricted gift by Sue and Bob O Donnell. The work of Angelo Maria Pezzullo in this research has been supported by the European Network Staff Exchange for Integrating Precision Health in the Healthcare Systems project (Marie Skłodowska-Curie Research and Innovation Staff Exchange no. 823995). Cathrine Axfors has received funding outside this work from the Knut and Alice Wallenberg Foundation s Postdoctoral Fellowship (KAW 2019.0561) and postdoctoral grants from Uppsala University (E o R Borjesons stiftelse; Medicinska fakultetens i Uppsala stiftelse for psykiatrisk och neurologisk forskning), The Sweden-America Foundation, Foundation Blanceflor, Swedish Society of Medicine, and Marta och Nicke Nasvells fond. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Funding: The work of John Ioannidis is supported by an unrestricted gift by Sue and Bob O’Donnell. The work of Angelo Maria Pezzullo in this research has been supported by the European Network Staff Exchange for Integrating Precision Health in the Healthcare Systems project (Marie Skłodowska-Curie Research and Innovation Staff Exchange no. 823995). Cathrine Axfors has received funding outside this work from the Knut and Alice Wallenberg Foundation’s Postdoctoral Fellowship (KAW 2019.0561) and postdoctoral grants from Uppsala University (E o R Börjesons stiftelse; Medicinska fakultetens i Uppsala stiftelse för psykiatrisk och neurologisk forskning), The Sweden-America Foundation, Foundation Blanceflor, Swedish Society of Medicine, and Märta och Nicke Nasvells fond. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

  • Conflicts of interest: None

  • Ethical approval: not applicable

  • Data sharing statement: All data are in the manuscript and supplementary files.

Data Availability

All data produced in the present work are contained in the manuscript

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted June 29, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Differential COVID-19 infection rates in children, adults, and elderly: evidence from 38 pre-vaccination national seroprevalence studies
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Differential COVID-19 infection rates in children, adults, and elderly: evidence from 38 pre-vaccination national seroprevalence studies
Cathrine Axfors, Angelo Maria Pezzullo, Despina G. Contopoulos-Ioannidis, Alexandre Apostolatos, John P.A. Ioannidis
medRxiv 2022.06.28.22277034; doi: https://doi.org/10.1101/2022.06.28.22277034
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Differential COVID-19 infection rates in children, adults, and elderly: evidence from 38 pre-vaccination national seroprevalence studies
Cathrine Axfors, Angelo Maria Pezzullo, Despina G. Contopoulos-Ioannidis, Alexandre Apostolatos, John P.A. Ioannidis
medRxiv 2022.06.28.22277034; doi: https://doi.org/10.1101/2022.06.28.22277034

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (557)
  • Anesthesia (135)
  • Cardiovascular Medicine (1769)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (316)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10812)
  • Forensic Medicine (8)
  • Gastroenterology (594)
  • Genetic and Genomic Medicine (2960)
  • Geriatric Medicine (288)
  • Health Economics (534)
  • Health Informatics (1933)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (293)
  • HIV/AIDS (633)
  • Infectious Diseases (except HIV/AIDS) (12525)
  • Intensive Care and Critical Care Medicine (696)
  • Medical Education (300)
  • Medical Ethics (87)
  • Nephrology (324)
  • Neurology (2808)
  • Nursing (152)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1473)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (868)
  • Pharmacology and Therapeutics (367)
  • Primary Care Research (338)
  • Psychiatry and Clinical Psychology (2646)
  • Public and Global Health (5383)
  • Radiology and Imaging (1016)
  • Rehabilitation Medicine and Physical Therapy (597)
  • Respiratory Medicine (727)
  • Rheumatology (330)
  • Sexual and Reproductive Health (290)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (48)
  • Transplantation (150)
  • Urology (126)